Back to News
Market Impact: 0.32
Roche's Susvimo Wins EU Approval For Neovascular Age-Related Macular Degeneration
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
The European Commission approved Roche's Susvimo (ranibizumab 100 mg/mL) to treat adults with neovascular age-related macular degeneration. The authorization expands Roche's commercial opportunity in the European ophthalmology market and is a positive regulatory milestone for the product.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
More News
- Roche obesity drug shows 15.5% weight loss in diabetes trial
- Why is Celldex Therapeutics stock sliding today?
- Is Regeneron Stock a Bargain Below $800?
- [Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity
- Trump Says US Team Met With Iranians at UNGA
- Paramount will need to release way more movies to make this merger work